Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults
Open Access
- 1 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 2 (1), vdaa142
- https://doi.org/10.1093/noajnl/vdaa142
Abstract
“Diffuse midline glioma (DMG), H3 K27M-mutant” is a new tumor entity established in the 2016 WHO classification of Tumors of the Central Nervous System that comprises a set of diffuse gliomas arising in midline structures and is molecularly defined by a K27M mutation in genes encoding the histone 3 variants H3.3 or H3.1. While this tumor entity is associated with poor prognosis in children, clinical experience in adults remains limited. Patient demographics, radiologic and pathologic characteristics, treatment course, progression, and patient survival were collected for 60 adult patients with DMG, H3 K27M-mutant. A subset of tumors also underwent next-generation sequencing. Analysis of progression-free survival and overall survival was conducted using Kaplan–Meier modeling, and univariate and multivariate analysis. Median patient age was 32 years (range 18–71 years). Tumors were centered in the thalamus (n = 34), spinal cord (10), brainstem (5), cerebellum (4), or other midline sites (4), or were multifocal (3). Genomic profiling revealed p.K27M mutations exclusively in the H3F3A gene and an absence of mutations in HIST1H3B or HIST1H3C, which are present in approximately one-third of pediatric DMGs. Accompanying mutations in TP53, PPM1D, FGFR1, NF1, and ATRX were frequently found. The overall survival of this adult cohort was 27.6 months, longer than historical averages for both H3 K27M-mutant DMG in children and IDH-wildtype glioblastoma in adults. Together, these findings indicate that H3 K27M-mutant DMG represents a heterogeneous disease with regard to outcomes, sites of origin, and molecular pathogenesis in adults versus children.Keywords
Funding Information
- National Institutes of Health (DP5 OD021403)
- National Cancer Institute
- UCSF Brain Tumor SPORE (P50 CA097257)
- UCSF Glioblastoma Precision Medicine Program
This publication has 37 references indexed in Scilit:
- Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomasJournal of Neuro-Oncology, 2019
- Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene ExpressionCancer Cell, 2018
- H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosisClinical Neuropathology, 2018
- Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine GliomaCancer Cell, 2017
- Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working groupEuropean Journal Of Cancer, 2017
- Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patientsJournal of Neuro-Oncology, 2016
- Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategiesOncotarget, 2016
- H3F3A K27M mutations in thalamic gliomas from young adult patientsNeuro-Oncology, 2013
- Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor SpecimensThe Journal of Molecular Diagnostics, 2013
- Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric OncologistThe Oncologist, 2004